Baudax Bio, Inc. (BXRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
BXRX POWR Grades
- Growth is the dimension where BXRX ranks best; there it ranks ahead of 77.32% of US stocks.
- BXRX's strongest trending metric is Growth; it's been moving up over the last 112 days.
- BXRX's current lowest rank is in the Stability metric (where it is better than 0.15% of US stocks).
BXRX Stock Summary
- BAUDAX BIO INC's market capitalization of $4,007,838 is ahead of only 1.28% of US-listed equities.
- In terms of volatility of its share price, BXRX is more volatile than 98.15% of stocks we're observing.
- BAUDAX BIO INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -458.63%, greater than the shareholder yield of only 1.46% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to BAUDAX BIO INC are AYTU, PTPI, OBLG, GOCO, and XRAY.
- BXRX's SEC filings can be seen here. And to visit BAUDAX BIO INC's official web site, go to www.baudaxbio.com.
BXRX Valuation Summary
- BXRX's EV/EBIT ratio is -0.1; this is 101.52% lower than that of the median Healthcare stock.
- BXRX's price/sales ratio has moved NA NA over the prior 41 months.
Below are key valuation metrics over time for BXRX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BXRX | 2023-03-24 | 3.2 | -0.2 | -0.1 | -0.1 |
| BXRX | 2023-03-23 | 3.2 | -0.2 | -0.1 | -0.1 |
| BXRX | 2023-03-22 | 3.2 | -0.2 | -0.1 | -0.1 |
| BXRX | 2023-03-21 | 3.3 | -0.2 | -0.1 | -0.1 |
| BXRX | 2023-03-20 | 3.3 | -0.2 | -0.1 | -0.1 |
| BXRX | 2023-03-17 | 3.6 | -0.2 | -0.1 | -0.1 |
BXRX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BXRX has a Quality Grade of F, ranking ahead of 1.16% of graded US stocks.
- BXRX's asset turnover comes in at 0.011 -- ranking 79th of 81 Healthcare stocks.
- 500 - Internal server error
The table below shows BXRX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.011 | -2.189 | -5.026 |
| 2021-06-30 | 0.008 | -3.584 | -4.211 |
| 2021-03-31 | 0.010 | -2.695 | -14.661 |
| 2020-12-31 | 0.007 | -2.513 | 28.623 |
| 2020-09-30 | 0.006 | -1.854 | 20.273 |
| 2020-06-30 | 0.006 | -0.862 | 40.097 |
BXRX Price Target
For more insight on analysts targets of BXRX, see our BXRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $2.00 | Average Broker Recommendation | 1.25 (Strong Buy) |
BXRX Stock Price Chart Interactive Chart >
BXRX Price/Volume Stats
| Current price | $1.71 | 52-week high | $76.80 |
| Prev. close | $1.70 | 52-week low | $1.25 |
| Day low | $1.65 | Volume | 196,900 |
| Day high | $1.78 | Avg. volume | 1,358,482 |
| 50-day MA | $2.38 | Dividend yield | N/A |
| 200-day MA | $11.99 | Market Cap | 4.42M |
Baudax Bio, Inc. (BXRX) Company Bio
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includes RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; and RP2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and a reversal agent, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Latest BXRX News From Around the Web
Below are the latest news stories about BAUDAX BIO INC that investors may wish to consider to help them evaluate BXRX as an investment opportunity.
Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business UpdateCompany Focuses on Development of Neuromuscular Blocking Agents Phase II Randomized Trial for BX1000 Initiated, Positive Interim Results Announced; Completion of Study Enrollment Expected Q1 2023, Top Line Results Expected Early Q2 2023 BX2000 Dose Escalation Study Progressing $5 Million in Financing Secured through Public Offering MALVERN, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital a |
Stocks Static As Earnings Season Heats UpAfter a strong start to the week, stocks are struggling for direction today as investors unpack the latest batch of earnings reports. |
Why Is Baudax Bio (BXRX) Stock Up 50% Today?BXRX stock is soaring today as Baudax Bio's novel medical product could result in time and cost savings for patients and hospitals. |
Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000MALVERN, Pa., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the successful outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery. “We are encouraged by the results of the first interim analysis of the BX1000 Phase II surgery trial,” said Gerri Henwood, Baudax Bio’s President and Chief E |
The 7 Most Sold-Off Stocks of 2022With 2022 rapidly coming to a close, it’s time to take a look back at the most sold-off stocks so you know which names to avoid. |
BXRX Price Returns
| 1-mo | -16.18% |
| 3-mo | -46.23% |
| 6-mo | -82.61% |
| 1-year | -97.58% |
| 3-year | -99.95% |
| 5-year | N/A |
| YTD | -46.23% |
| 2022 | -98.96% |
| 2021 | -78.30% |
| 2020 | -85.40% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...